Anaphore is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Our novel Atrimer™ drug candidates are engineered from a fully-human serum protein that is naturally secreted as a trimeric structure of approximately 60 kilodaltons.

Our proprietary TrimerX™ protein engineering platform provides multiple approaches to generate Atrimer™ protein therapeutics with biological, manufacturing and commercial advantages over traditional drugs such as antibodies, smaller protein scaffolds, and small molecules.